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Abstract—During angiogenesis, a combined action between newly secreted extracellular matrix proteins and the repertoire
of integrins expressed by endothelial cells contributes in the regulation of their biological functions. Extracellular
matrix-engaged integrins influence tyrosine kinase receptors, thus promoting a regulatory cross-talk between adhesive
and soluble stimuli. For instance, vitronectin has been reported to positively regulate VEGFR-2. Here, we show that
collagen I downregulates VEGF-A–mediated VEGFR-2 activation. This activity requires the tyrosine phosphatase
SHP2, which is recruited to the activated VEGFR-2 when cells are plated on collagen I, but not on vitronectin.
Constitutive expression of SHP2C459S mutant inhibits the negative role of collagen I on VEGFR-2 phosphorylation.
VEGFR-2 undergoes internalisation, which is associated with dynamin II phosphorylation. Expression of SHP2C459S
impairs receptor internalisation suggesting that SHP2-dependent dephosphorylation regulates this process. These
findings demonstrate that collagen I in provisional extracellular matrix surrounding nascent capillaries triggers a
signaling pathway that negatively regulates angiogenesis. (Circ Res. 2006;98:45-54.)
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Angiogenesis takes place during development, tissuegrowth and repair, and aberrantly in several pathological
settings. During angiogenesis, endothelial cells (ECs) modify
their genetic program. The final consequences are the as-
sumption of a migratory phenotype, cell cycle activation, and
the secretion of proteases and proteins of the extracellular
matrix (ECM).1 Changes in ECM physico-chemical features
are crucial for EC biological functions.2,3 In the resting
vasculature, ECM is mainly composed by collagens, laminin,
tenascin, proteoglycans, and perleclan;4 such environment
favors cell–cell adhesion, survival, and inhibits cell prolifer-
ation and migration.2,3 In contrast, provisional ECM sur-
rounding angiogenic ECs include new proteins such as
fibronectin, fibrin, vitronectin, collagen I, and throm-
bospondin. Furthermore, this ECM contains proteolytic
cleavage products of laminin, fibronectin, and collagens
generated by metalloproteinases released by activated ECs.2,3
A balance between negative and positive cues triggered by
provisional ECM is permissive for neovascularization.2,3 For
example, collagen I5 and thrombospondin-16 prevent angio-
genesis, whereas fibronectin shows opposite activities.7 Fur-
thermore, the proteolytic of laminin, collagen, and fibronectin
generates pro- and antiangiogenic fragments.2,3
Coordinated with these ECM modifications, ECs adapt
their repertoire of integrins to allow adhesion to new ECM
components and to receive instructive signals from surround-
ing microenvironment.2,3 In particular, the induction of an
angiogenic phenotype is associated with the expression of
v3, v5, and 51.8 –10 Actually, vascular endothelial
growth factor (VEGF)-A and fibroblast growth factor-2
induce angiogenesis that is, respectively, inhibited by block-
ing v5 and v3 function.11
VEGF-A represents a rate-limiting step for physiologic and
pathologic angiogenesis.12 VEGF-A activates VEGF receptor
(R) R-1 and VEGFR-2, the latter being the principal target of
the ligand in adult life. Different mechanisms are involved in
the fine-tuning of VEGFR-2 signaling:12,13 (1) VEGFR-2
transcription is regulated by soluble molecules and hypoxia;
(2) the catalytic activity of VEGFR-2 may be negatively
regulated by VEGFR-1, tissue inhibitor of metalloproteases
(TIMP)-2 and dopamine; (3) the association of VEGFR-2
with neuropilin-1 is instrumental for increasing its affinity
VEGF-A165; and (5) the localization in specific plasma
membrane domains is another mechanism to control
VEGFR-2 function. For example, in confluent ECs,
VEGFR-2 is mainly associated with adherens junctions and
mediates survival signals.14 On the contrary, during VEGF-
A–mediated EC migration, VEGFR-2 forms a complex with
v3 integrin.15–17 Finally, caveolae depletion results in an
increase of VEGFR-2 phosphorylation but leads to the
inhibition of downstream signals and EC motility.18
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Here, we demonstrate that fibrillar collagen I is a negative
modulator of VEGFR-2 activation via the recruitment of the
cytosolic Src homology-2 domain-containing protein tyrosine
phosphatase (SHP2)19,20 to the receptor. SHP2 dephosphory-
lates VEGFR-2 and favors its internalization. These findings
extend previous observations on the opposite effects exerted
by proteins of ECM on EC functions21,22 and provide new
insights into how ECM surrounding nascent vessels could
generate regulatory signals that are critical for EC response to
VEGF-A.
Materials and Methods
For details on reagents and plasmids, cells, cell motility, and
immunoprecipitation and immunoblotting, please see the online data
supplement available at http://circres.ahajournals.org.
Tyrosine Phosphatase Assay
Tyrosine phosphatase activity was measured on EC immunoprecipi-
tates anti-SHP1 and anti-SHP2 by HitHunter Fluorescence detection
tyrosine phosphatase assay kit (Discover, Fremont, Calif). Alterna-
tively, VEGFR-2 was immunoprecipitated as described from 107
human ECs stimulated with VEGF-A165 (0.23 nmol/L) and beads
were washed twice in 50 mmol/L 2-(N-morpholino)ethanesulphonic
acid, pH 6.5. VEGFR-2 immunoprecipitate was used as substrate and
incubated with the aforementioned immunoprecipitates in 2-(N-
morpholino)ethanesulphonic acid buffer for 1 hour at 37°C. At the
end of incubation, proteins were denatured, separated by SDS-
PAGE, and probed with mAb anti-pY or Ab anti–VEGFR-2.
VEGFR-2 Internalization
VEGFR-2 internalization was determined by evaluating the amount
of receptor that was resistant to trypsinization23 or by evaluating the
ratio between the amount of [125I-VEGF-A internalized and bound to
the cell surface.24 The methods are detailed in the online supplemen-
tary materials.
Fluorescence Resonance Energy Transfer Analysis
For fluorescence resonance energy transfer (FRET), PAE cells
carrying VEGFR-2-CFP and YFP-SHP2 were observed by a Leitz
orthoplan upright microscope (Leitz GMBH, Wetzlar, Germany)
equipped with an epi-illumination fluorescence detection system and
a temperature-controlled specimen holder at 33°C. Measurements
were made in a DMEM containing 2% fetal calf serum and
10 mmol/L HEPES (pH 7.4) exactly as previously described.25
Further details are described online.
Results
Effect of Type I Collagen and Vitronectin on
VEGF-A165–Induced EC Chemokinesis
Previous works demonstrated that ECM proteins modulate
the autophosphorylation activity of VEGFR-2 and its biolog-
ical responses.16,17,26 To further support this hypothesis, EC
chemokinesis-stimulated by VEGF-A165 was evaluated on
cells plated on collagen I or vitronectin by time-lapse video
microscopy of individual cells (Figure 1). ECs exhibited a
baseline mean migration speed of 17.310.09 m/hour on
vitronectin and 14.510.12 m/hour on collagen I
(P0.001; t test). In presence of VEGF-A165, EC speed
increased to 36.090.13 m/hour (P0.0001 versus un-
stimulated cells) and to 22.250.08 m/hour (P0.0002
versus unstimulated cells) on vitronectin and collagen I,
respectively. VEGF-A165 stimulation resulted in higher direc-
tional persistence of cell migration27; in contrast unstimulated
ECs moved in random directions. The VEGF-A165 effect was
more evident in cells plated on vitronectin. Unstimulated cells
on collagen I and on vitronectin showed a similar directional
persistence (vitronectin: 0.120.06; collagen I: 0.100.02),
whereas VEGF-A165 increased this parameter in a greater
extent in cells on vitronectin (0.430.05) than on collagen I
(0.190.04) (P0.0001) (Figure 1).
To exclude that the observed effects were caused by
different levels of VEGFR-2 expression, the high-affinity
binding sites of VEGF-A on the surface of EC plated on
collagen I or vitronectin were studied. Scatchard analysis
indicated that the type of ECM did not influence the number
of receptors and their affinity (supplemental Figure I).
Type I Collagen Inhibits VEGFR-2
Phosphorylation by Activating SHP2
Tyrosine Phosphatase
When VEGF-A165 stimulated ECs on vitronectin, VEGFR-2
phosphorylation was markedly higher as compared with cells
on collagen I,17 suggesting a modulating role of tyrosine
phosphatases.13,28–30 In particular, both SHP1 and SHP2 have
been demonstrated to negatively regulate VEGFR-2.13,28
Therefore, we measured phosphatase activity in SHP1 and
SHP2 immunocomplexes from VEGF-A165–stimulated ECs
adherent on native ECM. VEGF-A165 promoted a rapid
activation of SHP2 that peaked at 10 minutes and then
declined (Figure 2A). SHP-1 activity increased, but in slight
manner, without reaching a well-defined peak within 20
Figure 1. Tracks of ECs plated on vitronectin or collagen I. Pan-
els represent paths of cells (n9) tracked by video-lapse
microscopy in presence of VEGF-A165 (10 ng/mL) or vehicle over
a period of 5 hours. Cell paths are replotted such that all paths
start from the origin. The unit of measure on axes is m/h.
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minutes. On the basis of this observation and previous data
indicating that SHP2 is involved in GAS6 inhibition of
VEGFR-2,28 we pointed to this phosphatase. Our hypothesis
was further confirmed by the ability of SHP2 immunocom-
plexes isolated from VEGF-A165–stimulated ECs to dephos-
phorylate in vitro phosphorylated VEGFR-2 (Figure 2B;
supplemental Figure II). VEGF-A165 rapidly phosphorylated
SHP2 in tyrosine residues, an event known to be associated
with SHP2 catalytic activity19 (Figure 2C; supplemental
Figure II). Both catalytic activity (Figure 2D) and tyrosine
phosphorylation (Figure 2E; supplemental Figure II) stimu-
lated by VEGF-A165 were more pronounced in cells on
collagen I than on vitronectin.
SHP2 Binds VEGFR-2
Figure 3A shows that SHP2 associated with activated
VEGFR-2 immunoprecipitated from ECs on native ECM. To
further analyze this interaction, we performed a far Western
blot analysis using SHP2-GST fusion protein. Figure 3B and
supplemental Figure III show that phosphorylated VEGFR-2
Figure 2. VEGF-A165 activates SHP2. A and B, ECs (2107) grown on native ECM were stimulated with VEGF-A165 (solid line) (0.23 nmol/L) or
vehicle alone (dashed line) for the indicated times. Cell lysates were immunoprecipitated with anti-SHP2 () or anti-SHP1 (Œ) for phospha-
tase assay (meanSD; n5) (A). Alternatively SHP2 immunocomplexes were incubated for 1 hour at 37°C with phosphorylated VEGFR-2
immunopurified from ECs activated by its ligand as detailed in Methods. Denatured proteins were separated by SDS-PAGE and blotted as
indicated. Lane C indicates the initial level of VEGFR-2 phosphorylation incubated with a nonimmune anti-rabbit Ig immunocomplex from ECs
stimulated for 10 minutes with VEGF-A165 (B). C, ECs (2107) grown on native ECM were stimulated as before and SHP2 was immunopre-
cipitated. Solubilized proteins were divided in two aliquots and immunoblotted as indicated. D to E, ECs (2107) plated for 90 minutes on
collagen I or vitronectin were processed as described in (A and B). D, SHP2 phosphatase assay on unstimulated (dashed line) or VEGF-A165-
(0.23 mmol/L) stimulated (solid line) ECs plated on collagen I () or vitronectin (Œ). MeanSD of five experiments. E, Tyrosine phosphoryla-
tion of immunoprecipitated SHP2 from ECs plated on collagen I or vitronectin and stimulated with VEGF-A165 (5 minutes; 0.23 mmol/L). B, C,
and E, Representative of at least 3 experiments. Densitometric analysis of (B,C, E) are in supplemental Figure II.
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bound SHP2-GST in a time dependent-manner. To follow
this interaction in living cells, we analyzed FRET of VEGFR-
2-CFP and YFP- SHP2 in PAE stimulated with VEGF-A165.
Figure 3C and 3D shows that FRET occurred at the plasma
membrane level and disappeared when VEGF-A165 was re-
moved from medium.
Type I Collagen Elicits SHP2 Interaction
With VEGFR-2
Next, we investigated whether ECM could modulate the
association of SHP2 with VEGFR-2. VEGFR-2 was immu-
noprecipitated from ECs on collagen I or on vitronectin and
the association with SHP2 was analyzed. The amount of
Figure 3. SHP2 binds VEGFR-2. A and B, ECs (307) were grown on native ECM and stimulated with VEGF-A165 (0.23 nmol/L) or vehi-
cle alone. Cell lysates were immunoprecipitated with Ab anti–VEGFR-2. Immunoprecipitate was divided in 2 (A) or 3 (B) aliquots and
probed with the indicated Abs or with GST-SHP2 protein. Results are representative of 4 experiments and the densitometric analysis of
panel B is reported in supplemental Figure III. C, FRET analysis of PAE cells coexpressing VEGFR-2-CFP and SHP2- YFP with a ratio
1:1 or 1:2 and stimulated with VEGF-A165 for the indicated length of times. Degree of FRET efficiency was indicated by scale color from
blue to yellow. D, From the images in C, the FRET efficiency in a membrane portion was calculated. C and D, Representative of 25
cells, each obtained from 3 independent transfections. Variations within single experiments do not exceed 3% and between different
experiments do not exceed 7%. E, ECs (3107) were plated for 90 minutes on collagen I or on vitronectin and stimulated for the indi-
cated times with VEGF-A165 (0.23 nmol/L). Cell lysates were immunoprecipitated, divided in 3 aliquots and blotted as indicated. Results
are representative of 3 experiments and the densitometric analysis is reported in supplemental Figure III.
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associated SHP2 with VEGFR-2 in cells on vitronectin was
much reduced compared with cells on collagen I (Figure 3E;
supplemental Figure III). In these experiments EC adhesion
to ECM substrates was similar, thus excluding the possibility
that the observed effect could be caused by differences in
cells adhesion (not shown).
Effect of SHP2C459S Overexpression on
VEGFR-2 Activation
To investigate the involvement of SHP2 in VEGFR-2 signal-
ing, ECs were infected with a retroviral vector carrying
SHP2C459S dominant-negative mutant31 (Figure 4A), plated on
collagen I, and stimulated with VEGF-A165 for different
lengths of time. The amount of VEGFR-2 was not modified
by the constitutive expression of the transgene (supplemental
Figure IV), suggesting that the results obtained were not
dependent on a modification of the basal expression of
VEGFR-2. The expression of SHP2C459S mutant enhanced
VEGFR-2 phosphorylation after 15 minutes of stimulation
with VEGF-A165 as compared with ECs infected with vector
alone (Figure 4B and 4C).
When EC infected with vector alone (EC-Pinco) were
plated on collagen I (Figure 4D and 4E) VEGFR-2 phosphor-
ylation triggered by VEGF-A165 was lower than on vitronec-
tin. The pre-incubation with orthovanadate resulted in in-
crease VEGFR-2 phosphorylation, which was particularly
evident in stimulated cells on collagen I. Accordingly,
SHP2C459S overexpression abrogated the increased VEGFR-2
Figure 4. Effect of overexpression of
SHP2C459S on VEGFR-2 activation. A,
ECs were infected with a retroviral vector
encoding SHP2C459S and the expression
of the proteins was analyzed on cell
lysate by immunoblot. B, Infected cells
(2107) plated on collagen I were stimu-
lated for the indicated times with VEGF-
A165 (0.23 nmol/L). Cell lysates were
immunoprecipitated as indicated. C,
Densitometric analysis of the experiment
shown in (B). MeanSD of 4 experi-
ments. ANOVA was F77.55. §P0.05
vs unstimulated cells. *P0.05 vs cells
carrying vector alone. White and black
bars, respectively, indicate EC-PINCO
and EC-SHP2C459S. D, Cells plated on
collagen I or on vitronectin were pre-
treated with orthovanadate (1 mmol/L, 15
minutes) and then treated VEGF-A165
(0.23 nmol/L) for 10 minutes. After immu-
noprecipitation, samples were divided in
2 aliquots, run in two gels, and immuno-
blotted as indicated. E, Densitometric
analysis of the experiment shown in (D).
MeanSD of 5 experiments. Before
ANOVA (F31.04) data were normalized
according to z score §P0.05 vs
unstimulated cells plated on collagen I or
vitronectin. *P0.05 vs cells plated on
collagen I and stimulated with VEGF-
A165. White and black bars, respectively,
indicate EC-Pinco and EC-SHP2C459S.
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phosphorylation caused by orthovanadate. When EC-
SHP2C459S were plated on vitronectin, VEGFR-2 phosphory-
lation was completely unaffected by orthovanadate treatment
(Figure 4D and 4E). These data support the concept type I
collagen modulates VEGFR-2 through SHP2.
Because the chemokinetic activity of VEGF-A165 was low
on EC plated on collagen I (Figure 1), we investigated the
rescuing effect of the expression of SHP2C459S. The baseline
migration speed on EC-Pinco and EC-SHP2C459S was similar
(13.920.22 m/hour and 14.210.42 m/hour, respec-
tively) and was increased 1.5- to 2-fold by VEGF-A165
(EC-Pinco: 20.330.26 m/hour; EC-SHP2C459S:
25.820.28 m/hour). Analysis of directional persistence
demonstrated that the expression of the mutant did not
modify the resting values (EC-Pinco: 0.090.04; EC-
SHP2C459S: 0.120.08), whereas it allowed VEGF-A165 to be
more efficient (EC-Pinco: 0.200.06; EC-SHP2C459S:
0.320.07) (Figure 5). The expression of SHP2C459S did not
affect the chemokinetic parameters of unstimulated or stim-
ulated cells plated on vitronectin, which were completely
comparable to those shown in Figure 1(data not shown).
SHP2 Regulates VEGFR-2 Internalization
On engagement with its ligands, VEGFR-2 is internal-
ized.18,24,32,33 Recent data suggest that dephosphorylation of
tyrosine kinase receptors by protein phosphatases is involved
in their downregulation through internalization.34–36
Therefore, we looked at the internalisation of VEGFR-2 in
ECs overexpressing SHP2C459S. To discriminate between the
receptor exposed on cell membrane and the internalized
fraction, cell surface was treated with trypsin23,35 and
VEGFR-2 was immunoprecipitated with an Ab raised against
its cytosolic portion. This method allows a direct analysis of
receptor endocytosis by means trypsin-directed proteolysis of
the membrane-exposed receptor. The internalized VEGFR-2
is in fact the only one retaining the original mass, whereas the
receptor molecules that remain on the cell surface are cleaved
by trypsin. This assay is an indirect indication of endocytosis,
even though it does not offer any indication of the intracel-
lular fate of the receptor.23,35 VEGFR-2 endocytosis was
detectable 10 minutes after stimulation and reached the peak
at 15 minutes (Figure 6A and 6B). Very little amount of
internalized VEGFR-2 was detected in ECs overexpressing
SHP2C459S. These results were confirmed by internalisation
analysis of [125I]VEGF-A. Expression of SHP2C459S reduced
the internalisation of the ligand (Figure 6C).
The GTPase dynamin II is a regulator of both clathrin- and
caveolae-dependent endocytosis and its activity is positively
regulated by tyrosine phosphorylation.37,38 In ECs dynamin II
is a substrate of Src kinase,39 which is activated by VEGF-
A.33,40 Furthermore, SHP2 regulates Src by controlling phos-
phorylation of its inhibitory tyrosine 529.41 If SHP2 contrib-
utes to the VEGFR-2 endocytosis, Src and dynamin II should
be inhibited in cells carrying SHP2C459S. Indeed, VEGF-A165–
evoked tyrosyl phosphorylation of dynamin II and phosphor-
ylation of Src Tyr-416 were impaired in these cells (Figure
6D and 6E; supplemental Figure V). These data demonstrate
that SHP2 stimulation by VEGFR-2 modulates dynamin II
activation, probably through Src kinase activation.
SHP2 Binds Directly to Tyrosine 1173 in
the VEGFR-2
C-terminal Tyr-1212 and -1173 are the two major VEGF-A–
dependent autophosphorylation sites42 and their removal
impairs VEGFR-2 downregulation,43 suggesting that one of
these Tyr residues could binds SHP2. VEGFR-2 and its
mutants VEGFR-2Y1173F and VEGFR-2Y1212F were immunopre-
cipitated from transfected PAE cells and the association with
SHP2 was analyzed by immunoblot. The VEGF-A165–depen-
dent tyrosine phosphorylation of the receptor was lower in
PAE carrying VEGFR-2Y1173F and VEGFR-2Y1212F mutants
than in cells transfected with wild type receptor accordingly
to the relevance of these residues in the autophosphorylation
event (Figure 7A). Mutation in tyrosine 1173 abrogated the
interaction with SHP2, suggesting that this reside is crucial
for SHP2 binding to VEGFR-2 (Figure 7B).
Discussion
Our study establishes a role for collagen I, a protein released
within the provisional ECM by angiogenic ECs, as a negative
regulator of VEGFR-2 through activation of tyrosine phos-
phatase SHP2. This concept parallels the observation that
11 integrin engaged by collagen activates the T-cell protein
tyrosine phosphatase function that inhibits epidermal growth
factor receptor signaling.44
We demonstrated that EC adhesion to collagen I reduces
VEGF-A165–induced VEGFR-2 autophosphorylation by re-
cruiting SHP2 to the phosphorylated tyrosine 1173. This
Figure 5. Effect of overexpression of SHP2C459S on EC chemoki-
nesis. Panels represent paths of EC-Pinco and EC- SHP2C459S
plated on collagen I (n9) in presence of VEGF-A165 as detailed
in legend to Figure 1. The unit of measure on axes is m/h.
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observation explains our previous data showing that EC
proliferation stimulated by VEGF-A165 is lower on collagen I
than on vitronectin.17 Moreover, we provide evidences that:
(1) EC motility induced by VEGF-A165 is enhanced on
vitronectin as compared with collagen I; (2) SHP2 activity
and tyrosine residue phosphorylation are activated by
VEGF-A when ECs adhere on native ECM or on vitronectin;
however, these effects are greatly increased when EC adhere
Figure 6. Effect of overexpression of SHP2C459S on VEGFR-2 internalization, dynamin II, and Src phosphorylation. ECs (2107) overex-
pressing SHP2C459S were plated on collagen I and stimulated for the indicated times with VEGF-A165 (0.23 nmol/L). A, Cells were sub-
mitted to trypsin treatment as described in Methods, and cell lysates were immunoprecipitated with an Ab anti the C-terminus of
VEGFR-2 and immunoblotted with an Ab anti–VEGFR-2. B, Densitometric analysis of the experiment shown in (A). MeanSD of 4
experiments. ANOVA was F21.50. §P0.05 vs unstimulated cells. *P0.05 vs SHP2C459S cells stimulated for 15 minutes with VEGF-
A165. White, black, and hatched bars, respectively, indicate EC, EC-Pinco, and EC-SHP2C459S. C, EC overexpressing SHP2C459S (Œ) or
vector alone () were incubated, then incubated at 37°C with [125I]VEGF-A. Internalization was monitored as outlined in Methods.
MeanSD of three samples in one experiment of two. D, Cell lysates were immunoprecipitated with Ab anti-dynamin II, divided in 2
aliquots, separated by SDS-PAGE and blotted as indicated. E, Total amount of Src and pY416 Src was detected by immunoblotting on
cell lysates. Results are representative of 7 (C) and 4 (D) experiments, respectively. Densitometric analysis of (C) and (D) is reported in
supplemental Figure VI.
Figure 7. SHP2 interacts with Y1173 of
VEGFR2. Wild-type and mutant VEGFR-2
cDNAs were transiently transfected in
PAE cells that were stimulated with
VEGF-A165. Lysates were immunoprecipi-
tated with anti–VEGFR-2 Ab and immu-
noblotted with anti-pY (A) or anti-SHP2
(B). Results are representative of at least
3 experiments.
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on collagen I; (3) constitutive expression of SHP2C459S blocks
the inhibition of VEGFR-2 phosphorylation observed in cells
adhering to collagen I; (4) VEGFR-2 is a substrate of SHP2;
(5) in living cells VEGFR-2 closely interacts with SHP2 in
proximity of plasma membrane of ECs; and (6) VEGF-A165
dependent association of VEGFR-2 with SHP2 occurs when
ECs are plated on collagen I, but not on vitronectin.
Downregulation of tyrosine kinase receptors by phospho-
tyrosine phosphatases could be considered a simpler and
faster way to modify their behavior and functions as com-
pared with clathrin-mediated or caveolae-dependent endocy-
tosis or to proteasome-mediated degradation.45 SHP2 has
been generally considered a positive downstream signal
activated by membrane receptors.46 However, emerging evi-
dences suggest that it may positively or negatively regulate
signaling pathways depending on the specific type of signal-
ing network. For example, SHP2 may act as a negative
regulator of platelet-derived growth factor receptor by induc-
ing dephosphorylation of the receptor itself or of its cognate
substrates.47–49 However, SHP2 is also implicated in positive
regulation of this receptor through regulation of Ras or focal
adhesion kinase.50,51 Similarly, SHP2 exerts both negative
and positive influences on T-cell receptor52,53 and JAKs/
STATs pathway.54,55 Finally, SHP2 exclusively acts as neg-
ative regulator in angiotensin II receptor A1-mediated
signals.56
Here, we do not investigate the precise mechanism by
which collagen I favors SHP2-mediated VEGFR-2 dephos-
phorylation. Recently, we have demonstrated that SHP2 is
involved in the negative control of VEGFR-2 triggered by
GAS6-dependent Axl stimulation.28 Furthermore, our obser-
vation parallels the results that VEGFR-2 may be negatively
regulated by TIMP-2 through SHP1.13 In ECs stimulated by
TIMP-2, SHP1 shifts from 31 integrin to VEGFR-2, which
is dephosphorylated.
It has been reported that in vascular smooth muscle cells
3 engagement by vitronectin results in tyrosine phosphory-
lation of its cytosolic domain and recruitment of SHP2, which
modulate insulin growth factor I receptor.57 Thus, we hypoth-
esize a protective role on VEGFR-2 signaling by vitronectin-
engaged v3, which recruits SHP2 and preserves the receptor
from phosphatase activity. In contrast, EC adhesion on
collagen I, which does not depend on v3 integrin, could
allow SHP2 interacting with VEGFR-2. Preliminary evi-
dences demonstrate that a phosphatase activity is associated
to 3 in ECs plated on vitronectin and stimulated by
VEGF-A165. However, 1 immunocomplexes do not contain
any phosphatase activity both in cells plated on collagen I and
vitronectin (S. Mitola, unpublished).
Then we showed that SHP2 plays a relevant role in
VEGFR-2 internalisation. VEGFR-2 undergoes endocytosis
by a Cbl-dependent ubiquitination process58 or through a
mechanism caveolin-1–dependent.18 Here, we extend these
observations by showing overexpression of SHP2C459S dra-
matically decreases VEGFR-2 internalization, suggesting that
dephosphorylation is involved in regulating its trafficking.
VEGF-A165 induced tyrosyl phosphorylation of dynamin II,
a GTPase regulator of vesicle fission required for the control
of both clathrin- and caveolae-mediated endocytosis.38 Pre-
vious studies showed that Src-dependent dynamin II phos-
phorylation is required for endocytosis.39,59,60 Furthermore,
SHP2 activates Src kinase by inhibiting the recruitment of
C-terminal Src kinase, which exerts its inhibitory role by
phosphorylating Tyr-529 of Src.41 Here, we show that over-
expression of SHP2C459S significantly reduced the effect of
VEGF-A165 on dynamin II phosphorylation and Src activa-
tion. These data suggest that SHP2 activation dephosphory-
lates VEGFR-2 and concomitantly activates Src kinase,
which triggers a dynamin-dependent receptor internalization.
SHP2 binds Tyr-1173 of stimulated VEGFR-2. This residue
seems important in internalisation process as demonstrated by
studying truncated receptors lacking Tyr-1173 and Tyr-
1212.61 This process occurs in ECs growing on native ECM,
as demonstrated by the data showing that this phosphatase is
also activated by VEGF-A165 in ECs adherent to this ECM
(Figures 2A, 2B, and 3) as well as in cells on collagen I. Here,
we did not address the behavior of the internalized VEGFR-2
in EC adhering on collagen I. VEGFR-2 could either be
accumulated in the endosomal compartment and degraded or
recycled to the membrane, thus allowing a different degree of
EC activation or a modified spatial regulation of the signal. It
is known that tyrosine kinase receptors may be translocated to
the nucleus.62 Notably, it has been recently reported that
VEGF-A through VEGFR-2 may be transferred to the nu-
cleus of migrating ECs.32 We may speculate that collagen I
mediated internalization of VEGFR-2 results in attenuation of
VEGFR-2–mediated signals or in activation of undefined EC
responses and that a modulation of SHP2-dependent mecha-
nism of internalization by ECM characterizes specific steps
of angiogenesis.
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